The use of inhaled corticosteriods for persistent asthma in infants and young children

Annals of Allergy, Asthma and Immunology

Volumn 92, Issue 4, 2004, Pages

  Berger, William E ^a   Shapiro, Gail G ^b  

^a Allergy & Asthma Associates of Southern California   (United States)

^b Asthma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE DISKHALER; FLUTICASONE DISKUS; FLUTICASONE PROPIONATE; NEDOCROMIL SODIUM; SALBUTAMOL; THEOPHYLLINE; UNCLASSIFIED DRUG;

ADRENAL INSUFFICIENCY; ASTHMA; BONE DEMINERALIZATION; CANDIDIASIS; CATARACT; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTACT DERMATITIS; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; COUGHING; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEVER; GLAUCOMA; GROWTH RETARDATION; HOARSENESS; HUMAN; INFANT; INHALATION SPACER; INHALATIONAL DRUG ADMINISTRATION; MEDICAL NEBULIZER; MEDLINE; METERED DOSE INHALER; NEBULIZATION; OTITIS MEDIA; PERSISTENT ASTHMA; PHARYNGITIS; POWDER INHALER; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RHINITIS; SINUSITIS; THROAT DISEASE; THRUSH; UNITED STATES; CHILD WELFARE; INFANT WELFARE; NEBULIZER; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; CHILD WELFARE; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT WELFARE; NEBULIZERS AND VAPORIZERS; TREATMENT OUTCOME; UNITED STATES;

EID: 3042805574     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1081-1206(10)61773-5     Document Type: Review

References (108)

1. American Lung Association, Epidemiology & Statistics Unit Research and Scientific Affairs. Trends in Asthma Morbidity and Mortality. New York, NY: American Lung Association; March 2003.
2. Pediatric Asthma: Promoting Best Practice. Guide for Managing Asthma in Children. Milwaukee, WI: American Academy of Allergy, Asthma & Immunology; 1999.
3. Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol. 1998;102:531-538.
4. Barnes PJ. Current issues for establishing inhaled corticosteroids as the anti-inflammatory agents of choice in asthma. J Allergy Clin Immunol. 1998;101:S427-S433.
5. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med. 1998;157:S1-S53.
6. Calpin C, Macarthur C, Stephens D, Feldman W, Parkin PC. Effectiveness of prophylactic inhaled steroids in childhood asthma: a systematic review of the literature. J Allergy Clin Immunol. 1997;100:452-457.
7. Powell CV, Everard ML. Treatment of childhood asthma: options and rationale for inhaled therapy. Drugs. 1998;55: 237-252.
8. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med. 1994;88:373-381.
9. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis. 1990;142:832-836.
10. Mahajan P, Okamoto LJ, Schaberg A, Kellerman D, Schoenwetter WF. Impact of fluticasone propionate powder on health-related quality of life in patients with moderate asthma. J Asthma. 1997;34:227-234.
11. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA. 1997;277:887-891.
12. Wennergren G, Kristjánsson S, Strannegård I-L. Decrease in hospitalization for treatment of childhood asthma with increased use of antiinflammatory treatment, despite an increase in the prevalence of asthma. J Allergy Clin Immunol. 1996;97: 742-748.
13. Carlsen KH. Exercise induced asthma in children and adolescents and the relationship to sports. Pediatr Allergy Immunol. 1998;9:173-180.
14. Pedersen S, Ramsgaard-Hansen O. Budesonide treatment of moderate and severe asthma in children: a dose response study. J Allergy Clin Immunol. 1995;95:29-33.
15. Price JF, Weller PH. Comparison of fluticasone propionate and sodium cromoglycate for the treatment of childhood asthma (an open parallel group study). Respir Med. 1995;89:363-368.
16. Kraemer R, Sennhauser F, Reinhardt M. Effects of regular inhalation of beclomethasone dipropionate and sodium cromoglycate on bronchial hyperreactivity in asthmatic children. Acta Paediatr Scand. 1987;76:119-123.
17. Edmunds AT, Goldberg RS, Duper B, et al, on behalf of the EMPHASIS research group. A comparison of budesonide 800 μg and 400 μg daily via Turbohaler with disodium cromoglycate via Spinhaler for asthma prophylaxis in children. Br J Clin Res. 1994;5:11-23.
18. Meltzer EO, Orgel HA, Ellis EF, Eigen HN, Hemstreet MP. Long-term comparison of three combinations of albuterol, theophylline, and beclomethasone in children with chronic asthma. J Allergy Clin Immunol. 1992;90:2-11.
19. Verbene AA, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med. 1997;156: 688-695.
20. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Pocock SJ, Kerrebijn KF. Effects of 22 months of treatment with inhaled corticosteroids and/or β-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. Am Rev Respir Dis. 1992;146:547-554.
21. Simons FE and the Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med. 1997;337:1659-1665.
22. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma-update on selected topics 2002. J Allergy Clin Immunol. 2002;110(Suppl):S141-S219.
23. Shapiro G, Bronsky EA, LaForce CF, et al. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr. 1998;132:976-982.
24. Waalkens HJ, van Essen-Zandvliet EE, Hughes MD, et al, The Dutch CNSLD Study Group. Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. Am Rev Respir Dis. 1993;148: 1252-1257.
25. American Hospital Formulary Service. Cromolyn sodium. In: McEvoy GK, editor. AHFS Drug Information 2002. Bethesda, MD: American Society of Health-System Pharmacists; 2002: 3608.
26. Stempel DA, Busse WW. Preface. J Allergy Clin Immunol. 1998;102:S1.
27. National Institutes of Health, National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program: Guidelines for the Diagnosis and Management of Asthma: Expert Panel Report 2. Bethesda, MD: National Institutes of Health; 1997. NIH publication 97-4051.
28. O'Callaghan C. Delivery systems: the science. Pediatr Pulmonol Suppl. 1997;15:51-54.
29. Bush A. Asthma in the child under five. Br J Hosp Med. 1996;55:110-114.
30. Foucard T. Aggressive treatment of childhood asthma with local steroids: good or bad? Allergy. 1996;51:367-371.
31. Szefler SJ. Clinical need for a nebulized corticosteroid. J Allergy Clin Immunol. 1999;104:162-168.
32. Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess. 2001;5:1-149.
33. O'Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax. 1997;52:S31-S44.
34. Everard ML, Clark AR, Milner AD. Drug delivery from jet nebulisers. Arch Dis Child. 1992;67:586-591.
35. Wildhaber JH, Devadason SG, Hayden MJ, Eber E, Summers QA, Le Souef PN. Aerosol delivery to wheezy infants: a comparison between a nebulizer and two small volume spacers. Pediatr Pulmonol. 1997;23:212-216.
36. Wildhaber JH, Dore ND, Wilson JM, Devadason SG, Le Souef PN. Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr. 1999;135: 28-33.
37. Closa RM, Ceballos JM, Gomez-Papi A, Galiana AS, Gutierrez C, Marti-Henneber C. Efficacy of bronchodilators administered by nebulizers versus spacer devices in infants with acute wheezing. Pediatr Pulmonol. 1998;26:344-348.
38. Delgado A, Chou KJ, Silver EJ, Crain EF. Nebulizers vs metered-dose inhalers with spacers for bronchodilator therapy to treat wheezing in children aged 2 to 24 months in a pediatric emergency department. Arch Pediatr Adolesc Med. 2003;157:76-80.
39. Chou KJ, Cunningham SJ, Crain EF. Metered-dose inhalers with spacers vs nebulizers for pediatric asthma. Arch Pediatr Adolesc Med. 1995;149:201-205.
40. Kacmarek RM, Hess D. The interface between patient and aerosol generator. Respir Care. 1991;36:952-976.
41. Bisgaard H, Nikander K, Munch E. Comparative study of budesonide as a nebulized suspension vs pressurized metered-dose inhaler in adult asthmatics. Respir Med. 1998;92:44-49.
42. Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child. 1993;69:130-133.
43. Agertoft L, Pedersen S. A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone proponate Diskhaler. J Allergy Clin Immunol. 1997;99:773-780.
44. Manjra AI, Price J, Lenney W, Hughes S, Barnacle H. Efficacy of nebulized fluticasone propionate compared with oral prednisolone in children with an acute exacerbation of asthma. Respir Med. 2000;94:1206-1214.
45. Price J, Lenney W, Duncan C, et al. HPA-axis effects of nebulized fluticasone propionate compared with oral prednisolone in childhood asthma. Respir Med. 2002;96:625-631.
46. Westbroek J, Saarlainen S, Laher M, O'Brien J, Barnacle H, Efthimiou J. Oral steroid-sparing effect of two doses of nebulized fluticasone propionate and placebo in patients with severe chronic asthma. Respir Med. 1999;93:689-699.
47. Terzano C, Ricci A, Burinschi V, Nekam K, Lahovsky J. Comparison of the efficacy of beclomethasone dipropionate and fluticasone propionate suspensions for nebulization in adult patients with persistent asthma. Respir Med. 2003; 97(Suppl):S35-S40.
48. Dempsey OJ, Humphreys M, Coutie WJ, Lipworth BJ. Relative lung delivery of fluticasone propionate via large volume spacer or nebuliser in healthy volunteers. Eur J Clin Pharmacol. 2001;57:637-641.
49. Webb MS, Milner AD, Hiller EJ, Henry RL. Nebulised beclomethasone dipropionate suspension. Arch Dis Child. 1986; 61:1108-1110.
50. Storr J, Lenney CA, Lenney W. Nebulised beclomethasone dipropionate in preschool asthma. Arch Dis Child. 1986;61: 602-603.
51. Delacourt C, Dutau G, Lefrançois G, Clerson P, on behalf of the Beclospin Clinical Development Group. Comparison of the efficacy and safety of nebulized beclometasone dipropionate and budesonide in severe persistent childhood asthma. Respir Med. 2003;97(Suppl):S27-S33.
52. Terzano C, Allegra L, Barkai L, Cremonesi G. Beclomethasone dipropionate versus budesonide inhalation suspension in children with mild to moderate persistent asthma. Eur Rev Med Pharmacol Sci. 2001;5:17-24.
53. Bisca N, Cernatescu I, Dragomir D, Iacomi A, Mirceau M, Orascanu D. Comparison of the efficacy and safety of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler in paediatric patients with moderate to severe exacerbation of asthma. Respir Med. 2003;97(Suppl):S15-S20.
54. Szefler SJ, Eigen H. Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma. J Allergy Clin Immunol. 2002;109:730-742.
55. Ilangovan P, Pedersen S, Godfrey S, Nikander K, Noviski N, Warner JO. Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. Arch Dis Child. 1993;68:356-359.
56. de Blic J, Delacourt C, Le Bourgeois M, et al. Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study. J Allergy Clin Immunol. 1996;98:14-20.
57. Grimfeld A, Lesbros D, Ostinelli J, Caswell C. Long-term study of nebulised budesonide in young children with moderate to severe asthma [abstract]. Eur Respir J. 1994;7(Suppl): 27S.
58. Pedersen S, Ramsgaard-Hansen O, Nikander K. Budesonide suspension for nebulisation in children with asthma. Eur Respir J. 1989;2:647S.
59. Wennergren G, Nordvall SL, Hedlin G, Moller C, Wille S, Asbrink Nilsson E. Nebulized budesonide for the treatment of moderate to severe asthma in infants and toddlers. Acta Paediatr. 1996;85:183-189.
60. Volovitz B, Soferman R, Blau H, Nussinovitch M, Varsano I. Rapid induction of clinical response with a short-term high-dose starting schedule of budesonide nebulizing suspension in young children with recurrent wheezing episodes. J Allergy Clin Immunol. 1998;101:464-469.
61. Vikre-Jørgensen J, Agertoft L, Pedersen S. Dose titration of nebulized budesonide in young children. Pediatr Pulmonol. 1997;23:270-277.
62. Kemp JP, Skoner D, Szefler SJ, Walton-Bowen K, Cruz-Rivera M, Smith JA. Once-daily budesonide inhalation suspension for asthma in infants and children 6 months to 8 years of age. Ann Allergy Asthma Immunol. 1999;83:231-239.
63. Baker JW, Mellon M, Wald J, Welch M, Cruz-Rivera M, Walton-Bowen K. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics. 1999;103:414-421.
64. Shapiro G, Mendelson L, Kraemer MJ, Cruz-Rivera M, Walton-Bowen K, Smith JA. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol. 1998;102:789-796.
65. Leflein JG, Szefler SJ, Murphy KR, et al. Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcomes trial. Pediatrics. 2002;109:866-872.
66. Dukes E, Ollendorf D, Mellon M, et al. The impact of budesonide inhalation suspension on symptom-free days and use of asthma related services in young children with asthma [abstract]. Am J Respir Crit Care Med. 1999;159:A761.
67. Mellon M, Dukes E, Ollendorf D, et al. Budesonide inhalation suspension improves symptom-free days and use of asthma related services in infants and young children [abstract]. Ann Allergy Asthma Immunol. 2000;84:161.
68. Rutten-van Mölken MP, van Doorslaer EK, Jansen MC, van Essen-Zandvliet EE, Rutten FF. Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma. Pharmacoeconomics. 1993;4:257-270.
69. Bisgaard H, Price MJ, Maden C, Olsen NA. Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus Babyhaler spacer in the treatment of asthma in preschool-aged children. Chest. 2001;120:1835-1842.
70. Booth PC, Wells NE, Morrison AK. A comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthma. Pharmacoeconomics. 1996;10:262-268.
71. Andersson F, Kjellman M, Forsberg G, Möller C, Arheden L. Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice. Ann Allergy Asthma Immunol. 2001;86:537-544.
72. Pulmicort Respules [package insert]. Wilmington, DE: Astra-Zeneca LP; 2003.
73. Mellon M, Leflein J, Walton-Bowen K, Cruz-Rivera M, Fitzpatrick S, Smith JA. Comparable efficacy of nebulizer administration with face mask or mouthpiece of budesonide inhalation suspension for infants and young children with persistent asthma. Am J Respir Crit Care Med. 2000;162:593-598.
74. Georgitis JW, McWilliams B, Walton-Bowen K, et al. Effective once-daily administration of budesonide inhalation suspension by nebulizer with face masks or mouthpieces for persistent asthma in infants and young children. Pediatr Asthma Allergy Immunol. 2001;15:3-13.
75. Mellon M, Fitzpatrick S, Cruz-Rivera M, et al. Safety of nebulized budesonide inhalation suspension (Pulmicort Respules) delivered via mouthpiece or face mask in children: effects of local drug exposure [abstract]. Ann Allergy Asthma Immunol. 2002;8:129.
76. Everard ML, Hardy JG, Milner AD. Comparison of nebulised aerosol deposition in the lungs of healthy adults following oral and nasal inhalation. Thorax. 1993;48:1045-1046.
77. Rubin BK. Nebulizer therapy for children: the device-patient interface. Respir Care. 2002;47:1314-1319.
78. Smaldone GC, McKenzie J, Cruz-Rivera M. Effect of nebulizer volume on drug delivery: budesonide inhalation suspension [abstract]. Am J Respir Crit Care Med. 2000;161:A36.
79. Smaldone GC, McKenzie J, Cruz-Rivera M, Hoag JE. Budesonide inhalation suspension is chemically compatible with other nebulizing formulations [abstract]. Chest. 2000;118:98S.
80. McKenzie J, Cruz-Rivera M, Hoag J. Pulmicort Respules is chemically compatible with nebulized Xopenex [abstract]. Am J Respir Crit Care Med. 2001;163:A588.
81. Grönberg S, Magnusson P, Bladh N. Chemical compatibility of budesonide inhalation suspension (Pulmicort Respules) with other nebulization products [abstract]. Am J Respir Crit Care Med. 2001;163:A588.
82. -1. Eur Respir J. 1996;9:2263-2272.
83. Ferguson AC, Spier S, Manjra A, Versteegh FG, Mark S, Zhang P. Efficacy and safety of high-dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide. J Pediatr. 1999;134:422-427.
84. LaForce CF, Pearlman DS, Ruff ME, et al. Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma. Ann Allergy Asthma Immunol. 2000;85:407-415.
85. Peden DB, Berger WE, Noonan MJ, et al. Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma. J Allergy Clin Immunol. 1998;102:32-38.
86. Katz Y, Lebas FX, Medley HV, Robson R, and the Fluticasone Propionate Study Group. Fluticasone propionate 50 μg bid versus 100 μg bid in the treatment of children with persistent asthma. Clin Ther. 1998;20:424-437.
87. Jónasson G, Carlsen K-H, Blomqvist P. Clinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids. Eur Respir J. 1998;12:1099-1104.
88. Turpeinen M and the HEICA Study Group. Helsinki Early Intervention Childhood Asthma (HEICA) study: inhaled budesonide halved the number of asthma exacerbations compared with inhaled disodium cromoglycate during 18 months of treatment. Eur Respir J. 2000;16:311s.
89. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054-1063.
90. Agertoft L, Pedersen S, Nikander K. Drug delivery from the Turbuhaler and Nebuhaler pressurized metered dose inhaler to various age groups of children with asthma. J Aerosol Med. 1999;12:161-169.
91. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child. 1990;65:308-310.
92. Agertoft L, Pedersen S. Importance of training for correct Turbuhaler use in preschool children. Acta Pediatr. 1998;87: 842-847.
93. Connett GJ, Warde C, Wooler E, Lenney W. Use of budesonide in severe asthmatics aged 1-3 years. Arch Dis Child. 1993;69:351-355.
94. Williams J. Fluticasone propionate in the treatment of asthma in children: efficacy and safety. Rev Contemp Pharmacother. 1998;9:581-590.
95. Roorda RJ, Mezei G, Bisgaard H, Maden C. Response of preschool children with asthma symptoms to fluticasone propionate. J Allergy Clin Immunol. 2001;108:540-546.
96. Volovitz B, Amir J, Malik H, Kauschansky A, Varsano I. Growth and pituitary-adrenal function in children with severe asthma treated with inhaled budesonide. N Engl J Med. 1993; 329:1703-1708.
97. Scott MB, Skoner DP. Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol. 1999; 104:S200-S209.
98. Szefler S, Fitzpatrick S, Cruz-Rivera M, Lyzell E. Lack of cataracts and other localized adverse events in children treated with nebulized Pulmicort Respules (budesonide inhalation suspension) [abstract]. Am J Respir Crit Care Med. 2001;163: A589.
99. Irani A-M, Cruz-Rivera M Fitzpatrick S, Hoag J, Smith JA. Effects of budesonide inhalation suspension on hypothalamic-pituitary-adrenal-axis function in infants and young children with persistent asthma. Ann Allergy Asthma Immunol. 2002;88:306-312.
100. Saha MT, Lalpalla P, Lenko HL. Growth of asthmatic children is slower during than before treatment with inhaled glucocorticoids. Acta Paediatr. 1997;86:138-142.
101. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343:1064-1069.
102. Skoner D, Szefler S, Welch M, Walton-Bowen K, Cruz-Rivera M, Smith JA. Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma. J Allergy Clin Immunol. 2000;105:259-268.
103. MacKenzie CA, Tsanakas J, Tabachnik E, et al. An open study to assess the long-term safety of fluticasone propionate in asthmatic children. International Study Group. Br J Clin Pract. 1994;48:15-18.
104. Price JF, Russell G, Hindmarsh PC, Weller P, Heaf DP, Williams J. Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma. Pediatr Pulmonol. 1997;24:178-186.
105. Eid N, Morton R, Olds B, Clark P, Sheikh S, Looney S. Decreased morning serum cortisol levels in children with asthma treated with inhaled fluticasone propionate. Pediatrics. 2002;109:217-221.
106. Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child. 2002; 87:457-461.
107. Patel L, Wales JK, Kibirige MS, Massarano AA, Couriel JM, Clayton PE. Symptomatic adrenal insufficiency during inhaled corticosteroid treatment. Arch Dis Child. 2001;85:330-334.
108. Boushey HA. Effects of inhaled corticosteroids on the consequences of asthma. J Allergy Clin Immunol. 1998;102: S5-S16.